Condition: Healthy Control · Opioid Use Disorder · Sponsor: Yale University
The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability.
This description comes directly from the study's public registry record.
Anahita Bassir Nia, MD · 203-974-7540 · anahita.bassirnia@yale.edu
Angelina Contreras · 203-626-1105 · angelina.contreras@yale.edu
Always discuss trial participation with your own doctor first.
| Connecticut Mental Health Center, Clinical Neuroscience Research Unit | New Haven, Connecticut, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05683184